[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obesity-and-overweight\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obesity-and-overweight":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,68,0,25,[9,47,77,102,130,160,182,214,242,266,299,324,355,383,415,452,480,509,533,562,590,614,647,670,699],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100579490","time-restricted-eating-and-healthy-eating-in-patients-with-metabolic-liver-disease-or-cancer-100579490",false,"NCT06824974","Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer","Feasibility Study of Time Restricted Eating and a Healthy Diet in Patients Receiving Liver-Directed Therapy for Hepatocellular Carcinoma","TRE+HE","Inclusion Criteria:\n\n1. Overweight or obese (BMI 27-45 kg\u002Fm2)\n2. Diagnosed with metabolic-dysfunction associated steatitic liver disease (MASLD\u002FNAFLD), metabolic-dysfunction associated steatohepatitis, cirrhosis or liver cancer (BCLC early to intermediate stage HCC)\n3. English or Spanish speaking over the age of 18.\n4. ECOG Performance Status ≤ 2.\n5. Usual nightly fasting \\\u003C12 hours\n6. Willing to comply with all study procedures\n7. Life expectancy of \\> 12 months\n\nExclusion Criteria:\n\n1. Advanced HCC, progression, and\u002For associated comorbidities\n2. Metastatic disease, tumor in vein, or ascites\n3. Advanced Cirrhosis (hypoalbuminemia\u002FChild-Pugh B+C).\n4. Poorly controlled or refractory (grade 3-4) hepatic encephalopathy\n5. Type 1 diabetes or self-reported hypoglycemia or hypoglycemic events by CGM\n6. Participation in another conflicting study that requires modification of diet or food timing.\n7. Patients on GLP-1 receptor agonists\n8. Uncontrollable eating pattern (e.g., wasting, Night Eating Syndrome, disordered eating habits, food insecurity)\n9. Medications that markedly impact metabolic study biomarkers.\n10. Other cancer in last 10 years (other than nonmelanoma skin cancer or carcinoma of the cervix in situ)\n11. Serious medical conditions such as chronic kidney disease, congestive heart failure, or any condition that would interfere with participation in the trial.\n12. Unresolved toxicity ≥ CTCAE Grade 2 from previous anti-cancer therapy\n13. Active alcohol abuse or less than 6 months of sobriety\n14. Participation in a trial of an investigational agent within the prior 30 days\n15. Pregnancy or lactating, positive hCG urine test.","ALL","18 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is a feasibility study that will collect data to assess the potential effect of nutritional intervention. This prospective single-site trial will enroll adult patients with liver diseases such as metabolic-dysfunction associated steatotic liver disease (MASLD), metabolic-dysfunction associated steatohepatitis (MASH), cirrhosis and\u002For hepatocellular carcinoma (HCC). Eligible individuals who are randomized to the intervention group will be enrolled in a six-month nutritional change program consisting of time-restricted eating plus targeted healthy changes in what they eat (TR-HE). The intervention includes dietary counseling visits with a study registered dietitian (RD) and motivational phone calls with a study Certified Health and Wellness Coach (HC). Individuals who are randomized to the control group or who elect to join the control group will be enrolled in a six-month period of observation and phlebotomy only. The main questions it aims to answer are:\n\nIs a prolonged nightly fast coupled with a healthy diet safe and feasible for patients with liver disease or cancer? Does the intervention improve liver metabolism?",[28,29,30],"Liver Cancer, Adult","MASH - Metabolic Dysfunction-Associated Steatohepatitis","Obesity and Overweight",[32,33],"Time-restricted eating","healthy diet","RECRUITING","2026-06-22",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":38},"2025-08-01",{"date":42,"type":22},"2028-12",{"name":44,"class":45},"University of California, San Diego","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":75,"locationsCount":4},"100619603","evaluation-of-anterior-neck-ultrasound-in-predicting-difficult-airway-in-obese-patients-100619603","NCT07346768","Evaluation of Anterior Neck Ultrasound in Predicting Difficult Airway in Obese Patients","Ultrasound Assessment of Anterior Neck Soft Tissue Thickness to Predict Difficult Airway Risk in Obese Patients Undergoing for Surgery Under General Anesthesia: an Observational Study","Inclusion Criteria:\n\n* Age 18-70 years\n* ASA physical status I-III\n\n  \\* BMI \\>25 kg\u002Fm²\n* Scheduled for elective surgery under general anesthesia\n\nExclusion Criteria:\n\n* Emergency surgery\n* Pregnancy\n* Maxillofacial anomalies or neck masses\n* Rapid sequence induction\n* Previous history of difficult intubation\n* BMI \\>60 kg\u002Fm²","70 Years",{"count":56,"type":22},52,"OBSERVATIONAL","Obese patients are at increased risk of difficult airway management due to anatomical changes in the anterior neck soft tissues. Accurate preoperative prediction of difficult airway remains challenging using conventional clinical airway assessment tests alone.\n\nThis prospective observational study aims to evaluate the role of ultrasound assessment of anterior neck soft tissue thickness in predicting difficult airway risk in overweight and obese adult patients undergoing elective surgery under general anesthesia. Ultrasound-based anterior neck measurements will be compared with standard clinical airway assessment parameters to determine their diagnostic accuracy for difficult laryngoscopy and intubation.\n\nThe results of this study may contribute to improved preoperative airway risk stratification and safer airway management in obese patients.",[60,61,62,30],"Ultrasonography","Airway Management","Intubation, Intratracheal",[64,65,66,67],"Obesity","difficult airway","anterior neck ultrasound","ultrasonography","NOT_YET_RECRUITING","2026-06-12",{"date":71,"type":38},"2026-06-16",{"date":73,"type":22},"2026-06-20",{"date":73,"type":22},{"name":76,"class":45},"Gaziantep City Hospital",{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100616917","phase-3-efficacy-and-safety-of-met097-once-weekly-in-people-with-overweight-or-obesity-100616917","NCT07311850","Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity","Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)","VESPER-4","Inclusion Criteria:\n\n* BMI ≥ 30 kg\u002Fm2 or BMI ≥ 27.0 kg\u002Fm2 to \\\u003C30.0 kg\u002Fm2 and presence of at least 1 of the following weight- related comorbidities: Hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)\n\nExclusion Criteria:\n\n* Have any form of diabetes\n* Have a self-reported body weight change \\> 5 kg (11 pounds) within 3 months prior to Screening\n* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)\n* History of chronic pancreatitis or presence of acute pancreatitis within the past 180 days prior to the Screening visit; or active\u002Fcurrent, symptomatic gallbladder disease",{"count":86,"type":22},3501,[88],"PHASE3","This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.",[30],"2026-06-10",{"date":93,"type":38},"2026-06-11",{"date":95,"type":38},"2025-12-19",{"date":97,"type":22},"2028-04-25",{"name":99,"class":100},"Pfizer","INDUSTRY",170,{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":112,"conditions":113,"keywords":120,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":46},"100589244","identification-of-pre-surgical-phenotypic-indicators-predictive-of-quality-of-life-trajectories-in-obese-patients-following-bariatric-surgery-100589244","NCT06951893","Identification of Pre-surgical Phenotypic Indicators Predictive of Quality of Life Trajectories in Obese Patients Following Bariatric Surgery","PHENOBEQOL73","Inclusion Criteria:\n\n* patient \\> 18years old\n* Integrated into the GEROM73 surgical program and starting the intra-hospital program\n\nExclusion Criteria:\n\n* Patients in a state of psychiatric decompensation\n* Patients with cognitive disorders\n* Patients with difficulties understanding the French language, spoken or written\n* Pregnant, parturient, or breastfeeding women",{"count":110,"type":22},165,[25],"This study aims to identify pre-operative phenotypic determinants predictive of quality of life trajectories in post-bariatric surgery patients. In addition, this study will have as a secondary objective the highlighting of a potential link between post-surgery quality of life trajectories and those of anxiety\u002Fdepression scores, eating behaviors and body mass indices.\n\nThis study will be conducted during the usual care of patients undergoing the GEROM73 program, lasting a total of 30 months.\n\nThe GEROM73 program includes care for the six months preceding bariatric surgery and the 24 months following surgery. This program supports patients throughout their bariatric care..\n\nThroughout the GEROM73 program, patients will complete questionnaires on anxiety, depression, eating disorders, Impact of Weight on Quality Of Life.\n\nPatients' weight, body mass index and body schema will also be measured throughout the GEROM program.",[114,30,115,116,117,118,119],"Obesity, Morbid","Bariatric Surgery","Bariatric Surgery Patients","Bariatric Surgery Patient","Bariatric Surgery (Sleeve Gastrectomy )","Bypass, Gastric",[121,107],"GEROM73","2026-06-09",{"date":91,"type":38},{"date":125,"type":38},"2025-06-17",{"date":127,"type":22},"2030-09-09",{"name":129,"class":45},"Centre Hospitalier Metropole Savoie",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":138,"sex":18,"minAge":139,"maxAge":54,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":142,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":46},"100576496","phase-2-exploratory-study-on-postprandial-energy-metabolism-100576496","NCT06786052","EXploratory Study on Postprandial Energy Metabolism","Efficacy of Probiotics on Postprandial Energy Metabolism of Adults With Overweight or Obesity: an EXploratory Clinical Trial","EXPEM","Inclusion Criteria:\n\n1. Man or woman;\n2. Age between 50 and 70 years old (inclusively);\n3. Postmenopausal women, i.e. with amenorrhea for more than a year with no identified cause\n4. BMI between 27 and 34.9 kg\u002Fm2 (inclusively);\n5. Stable weight in the last 3 months (+\u002F- 5% of total body weight);\n6. Waist circumference ≥ 80 cm for women, ≥ 94 cm for men;\n7. Sedentary to moderately active (less than 30 minutes of moderate physical activity, 3 times a week);\n8. Agreeing not to consume fermented or supplemented foods (including bifidus yogurts and other foods supplemented with probiotics), dietary supplements (high in fiber (prebiotics), high protein, or other food supplements that may interact with the gut microbiota or energy metabolism), laxatives and any substance that can control metabolic parameters such as weight, blood glucose or lipid metabolism during the study period (from the screening visit);\n9. Agreeing to receive probiotics or placebo supplementation randomly;\n10. Able to understand the information given, read and write in French and have signed the informed consent form;\n11. Agreeing to submit to the entire study protocol;\n12. Having fibre consumption (through diet or supplementation) of less than 30g\u002Fday;\n13. Having a freezer to store stool samples before the visit.\n\nExclusion Criteria:\n\n1. Participant with unstable medical or psychological conditions that, in the opinion of the investigator, could lead the participant to be non-compliant or uncooperative during the study or that could compromise the safety or participation in the study (according to articles L.1121-6, L.1121-8, L.1121-9 and L1122-1-2 of the Public Health Code);\n2. Presence of pathology detectable on clinical examination and medical questioning that may interfere with the study endpoints;\n3. Alcohol consumption exceeding 30g of alcohol\u002Fday (1 dose of alcoholic beverage = 10g of alcohol) or abuse or dependence on another proven drug;\n4. Tobacco consumption (or vaping equivalent) \\> to 5 cigarettes per day and inability to restrict smoking or vaping on the exploratory days provided for in the protocol;\n5. Failure to comply with the exclusion period for another study specified in the \"national volunteer file\";\n6. Adult subject to a legal protection measure (guardianship, curatorship);\n7. Person deprived of liberty by a judicial or administrative decision;\n8. Person who has exceeded the annual amount of compensation in the year for participation in research protocols;\n9. Person not affiliated to a social security system or beneficiary of a similar system;\n10. Absence of valid approved health proof(s) in the event of government measures in an exceptional epidemic situation;\n11. Person with a specific diet (vegetarian, lacto-vegetarian, vegan, high-protein, etc.);\n12. People consuming food supplements (pre or probiotics, or minerals (divalent cations such as magnesium and calcium)) regularly during the month prior to the screening visit;\n13. Blood donation within 2 months prior to the screening visit;\n14. Claustrophobic to the point that indirect calorimetry measurement cannot be done;\n15. Person with limited venous access that can make it difficult to draw blood and insert a catheter;\n16. Type 1 or 2 diabetes;\n17. Systolic blood pressure ≥140 mmHg measured during the screening visit and mean systolic blood pressure from self-measurement over 3 days ≥140 mmHg;\n18. Diastolic blood pressure≥ 90 mmHg measured during the screening visit and mean diastolic blood pressure from self-measurement over 3 days ≥90 mmHg;\n19. Treatment for hypertension or dyslipidemia;\n20. Known endocrine pathology that may interfere with carbohydrate metabolism (uncontrolled dysthyroidism, acromegaly, hypercorticism, etc.);\n21. People with gastrointestinal pathologies with an inflammatory component or associated with malabsorption;\n22. People suffering from bloody diarrhoea;\n23. Exocrine pancreatic insufficiency;\n24. People who have had intestinal or abdominal surgery (apart from appendectomy and simple hernias), bariatric surgery (gastric banding, calibrated vertical gastroplasty and sleeve gastrectomy accepted if done more than 5 years ago);\n25. Severe eating disorders (e.g., anorexia\u002Fbulimia, uncontrolled binge eating syndrome, noctophagia);\n26. Chronic kidney failure;\n27. Hepatocellular insufficiency;\n28. Immunocompromised individuals (e.g., those with AIDS, lymphoma, patients on long-term corticosteroid therapy, patients undergoing chemotherapy and allogeneic transplants);\n29. Patients with central venous catheters and post-surgical patients;\n30. Hematological, gastrointestinal, hepatic, neurological, or psychiatric clinically significant according to the investigator;\n31. Drug treatments for obesity in the last 3 months or prescribed for the duration of the study;\n32. Taking antibiotics in the month preceding the explorations (for the so-called common antibiotics of the beta-lactam family) or in the 3 months preceding the explorations according to the investigator's judgment (for other families of antibiotics) except for certain types of antibiotics, particularly local or single-dose antibiotics: antibiotic eye drops (Oflocet), topical ointments (Fucidin), single-dose treatments (Monuril), and single-dose fosfomycin;\n33. Taking antidepressants in the 2 months prior to the explorations or prescribed for the duration of the study;\n34. Daily intake of laxatives in the 3 months prior to explorations or other medications that may strongly interfere with the composition of the gut microbiota;\n35. Taking a treatment that may interfere with the study measures, according to the judgment of the co-investigating physicians of the study.",true,"50 Years",{"count":141,"type":22},66,[143],"PHASE2","This exploratory, double-blinded clinical trial on 66 randomized adults aged 50 to 70 years with moderate overweight or obesity but considered metabolically healthy will consist of comparing metabolic and microbiota parameters before and after 3 months of consumption of a probiotic or a placebo.",[30,146],"Moderately Obese",[148,149,150],"Metabolic health","Probiotics","Postprandial metabolism","2026-05-26",{"date":153,"type":38},"2026-05-28",{"date":155,"type":38},"2025-04-07",{"date":157,"type":22},"2028-02",{"name":159,"class":100},"Lallemand Health Solutions",{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":46},"100588011","phase-2-effects-of-tirzepatide-on-weight-loss-and-chronic-inflammation-in-people-with-hiv-100588011","NCT06935838","Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV","Age ≥ 18 years\n\nHIV-1 infection (well controlled)\n\n* Documented HIV-1 infection ≥ 1 year prior to study entry (ELISA confirmed by Western blot or HIV-1 RNA) AND\n* HIV-1 RNA \\\u003C200 copies\u002FmL for ≥ 6 months\n\nStable ART\n\n· Receiving a stable antiretroviral regimen for at least 1 year prior to study entry\n\nOverweight\n\n* BMI ≥27 kg\u002Fm2 plus at least one weight-related condition (defined as a medical history of dyslipidemia, hypertension, cardiovascular disease, or obstructive sleep apnea) OR Obese\n* BMI ≥ 30 kg\u002Fm2",{"count":167,"type":22},12,[143],"This is a prospective cohort study of 12 overweight (with one or more weight-related condition) or obese adults with well controlled HIV-1 on antiretroviral therapy (ART). An initial dose of tirzepatide (TZP) 2.5 mg subcutaneous (SQ) once weekly will be given, escalated by 2.5 mg at 4-week intervals to a final dose of 7.5mg. The investigators will collect the following information via review of the medical record: age, race\u002Fethnicity, sex, medical conditions, medications, most recent standard of care HIV labs (including T-cell panel and HIV-1 viral load). The primary outcome will be the change in baseline body weight at 12 weeks. Secondary outcomes will be changes in body composition, liver fat content and liver stiffness, inflammatory markers, cardiometabolic markers (lipids and HbA1c), and monocytes at 12 weeks. There will be a 4-week safety follow up off TZP.",[30,171,172],"HIV","Chronic Inflammation","2026-05-22",{"date":175,"type":38},"2026-05-27",{"date":177,"type":38},"2025-11-12",{"date":179,"type":22},"2026-07-31",{"name":181,"class":45},"University of Hawaii",{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":138,"sex":18,"minAge":190,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":193,"briefSummary":194,"conditions":195,"keywords":199,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":46},"100596775","advancing-biopsychosocial-care-training-initiative-100596775","NCT07049861","Advancing Biopsychosocial Care Training Initiative","Increasing Access to USPSTF-Recommended Obesity Care for Youth and Adults Who Are Recipients of Medicaid: Evaluation of a Comprehensive Multidisciplinary Obesity Care Training Program in FQHCs","ABC Initiative","Study Eligibility Criteria - Provider Trainees:\n\n* Provider Trainees must be PCPs, BHPs, RDNs, or CHWs who work at participating clinics.\n\n  * PCPs that are eligible to participate as Provider Trainees can be any of the following: Medical Doctors (MD), Doctor of Osteopathic Medicine (DO), Physician Assistants (PA), or Nurse Practitioners (NP). PCPs must see patients in a primary care setting and be capable of referring patients to IBT and MNT. PCPs must have already completed their residency (when applicable).\n  * BHPs that are eligible to participate as Provider Trainees must be at least one of the following categories (listed with typical credentials): Licensed Clinical Social Worker (LCSW), Licensed Professional Counselor (LPC), Licensed Marriage and Family Therapist (LMFT), Psychologist (PhD\u002FPsyD), Psychiatric Nurse Practitioner, Psychiatrist (MD).\n  * RDNs that are eligible to participate as Provider Trainees must be Registered Dietitians\u002FRegistered Dietitian Nutritionists.\n  * CHWs must work as Community Health Workers, or in functionally similar role, within participating clinics\n\nStudy Eligibility - EHR Patients: Benefit-Eligible Patients from Participating Clinics\n\n* Benefit-Eligible Patients from Participating Clinics can either be youth (ages 5-20) or adults (ages 21+) and must be recipients of Medicaid, eligible for the MO Medicaid benefit (i.e., Medicaid recipients with obesity), and have been seen at participating FQHC clinics.\n\nExclusion Criteria - Provider Trainees:\n\n* Not at a participating clinic\n* PCPs who do not have the ability to refer to IBT or MNT\n* Resident Doctors\n* A doctor specializing in reproductive health (or related fields)\n\nExclusion Criteria - Benefit-Eligible Patients from Participating Clinics:\n\n* Patients without obesity\n* Patients not on Medicaid\n* Youth under the age of 5\n* Not a patient at a participating clinic","5 Years",{"count":192,"type":22},6200,[25],"This project will compare two training approaches for US Preventive Services Task Force recommended obesity care in Federally Qualified Health Centers (FQHC) across four aims. Aim 1 compares patient-level effectiveness \\[i.e., patient relative weight change and the proportion of patients who achieve clinically significant weight loss\\]. Aim 2 compares reach (patient treatment utilization). Aim 3 compares primary care provider (PCP) referrals to USPSTF-recommended care at 12 (adoption) and 24 months (maintenance) and short- and long-term changes in provider obesity care competencies . Aim 4 compares implementation and service costs.",[196,197,198,30,64],"Weight Management","Obesity Prevention","Obesity and Obesity-related Medical Conditions",[200,201,202,203,64,204],"Training","Implementation","Intensive Behavioral Treatment","Family-based Behavioral Treatment","Obesity Care","2026-05-18",{"date":207,"type":38},"2026-05-20",{"date":209,"type":38},"2025-07-14",{"date":211,"type":22},"2028-12-15",{"name":213,"class":45},"Washington University School of Medicine",{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":224,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":241},"100619383","impact-of-chia-seeds-on-human-breast-milk-composition-100619383","NCT07343908","Impact of Chia Seeds on Human Breast Milk Composition","An RCT: Impact of Chia Seeds on Human Breast Milk Composition","Inclusion Criteria:\n\n* pre-pregnancy BMI \\>25 kg\u002Fm²\n* Maternal age 18 - 45 years at time of delivery\n* Singleton pregnancy\n* Vaginal delivery\n* Intention to breast feed for at least three months\n* No prescription medications that may interfere with gut microbiome\n* Not taking antibiotics for ≥ 1 week prior to each visit\n* No chia seed supplements during pregnancy\n\nExclusion Criteria:\n\n* Inability to understand English\n* Preterm or post-term birth (gestational age \\\u003C37 or \\>42 weeks)\n* Congenital or other defect or medical condition that would affect the mother's ability to produce milk or the infant's growth or ability to breastfeed\n* Infant eating more than 12 ounces of any liquid other than breast milk in the two weeks prior to each study visit\n* Taking Antibiotics (all), Proton pump inhibitors\u002FH2 blockers, Metformin, NSAIDs, Statins, SSRIs and tricyclic antidepressants","45 Years",{"count":223,"type":22},80,[25],"The investigators' over-arching hypothesis is that mechanical and compositional properties of chia seeds supplemented during lactation diminish obesity-induced intestinal inflammation and barrier dysfunction. The investigators hypothesize these changes will result in: 1) reduced maternal systemic inflammation (serum CRP and IL-6) and increased gut microbial diversity and richness, 2) reduced HM fat and inflammatory markers, metrics the research team have demonstrated differ in tandem with maternal metabolic health and 3) improved infant growth\u002Fbody composition. To test these hypotheses, investigators will evaluate chia seed supplementation during lactation in a 6wk multi-site pilot RCT (Aim 1) and through translational studies using human enteroids (Aim 2).",[30,227],"Breastfeeding, Exclusive",[30,227,229,230,231],"Breastmilk","Body Composition","Infant Growth","2026-05-14",{"date":234,"type":38},"2026-05-15",{"date":236,"type":22},"2026-08",{"date":238,"type":22},"2027-12",{"name":240,"class":45},"University of Oklahoma",2,{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":264,"locationsCount":46},"100576812","study-of-patients-being-treated-with-anti-obesity-medication-100576812","NCT06790160","Study of Patients Being Treated With Anti-obesity Medication","Observational Study of Patients Being Treated With Anti-obesity Medication","Inclusion Criteria:\n\n* Patient who is beginning treatment through Vineyard Virtual Health Clinic using semaglutide or tirzepatide. While the physician will individualize the treatment plans, the criteria for these medications will include, at a minimum: (A) a body mass index ≥30 kg\u002Fm2; OR (B) a BMI ≥27 kg\u002Fm2 plus at least one comorbidity.\n* Patient who lives in drivable proximity to a city with an accepted DXA testing facility and is willing to report to the facility for periodic body composition testing.\n\nExclusion Criteria:\n\n* Patients with type 2 diabetes.\n* Patients who report not being willing or able to complete the assessments included in this research study.\n* Patients who are currently pregnant or trying to become pregnant.",{"count":250,"type":22},100,"The goal of this observational study is to learn about the real-world effects of selected obesity medications in adults undergoing medical weight management. The main outcomes of interest are changes in body composition, routine clinical markers, muscular performance, and nutritional intake over the course of treatment. Additionally, the influence of lifestyle factors on changes in these outcome variables will be examined.\n\nParticipants beginning treatment with selected obesity medications will undergo periodic body composition and muscular performance testing, as well as complete online surveys about their nutritional intake and physical activity and exercise participation. Additionally, routinely collected clinical information will be evaluated.",[30],[254,255,256,257,258],"obesity","GLP-1","body composition","nutrition","exercise","2026-05-13",{"date":234,"type":38},{"date":262,"type":38},"2025-01-31",{"date":238,"type":22},{"name":265,"class":45},"Texas Tech University",{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":138,"sex":18,"minAge":139,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":282,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":46},"100589043","metabolic-health-bones-and-nuts-during-weight-loss-in-adults-100589043","NCT06949280","Metabolic Health, Bones and Nuts During Weight Loss in Adults","Metabolic Health, Bones and Nuts Sources of Fatty Acids During Weight Loss in Adults","BERN","Inclusion Criteria:\n\n* Men and postmenopausal women (\\>2 years since last menses), ages 50-75 years\n* Body mass index (25-42 kg\u002Fm2) or evidence of pre-clinical obesity.\n* Agree to be randomly assigned to consume a daily peanut snack or nut-free snack for 24 weeks\n* Must attend on-site visits (about 10) in New Brunswick, NJ, USA (transportation\u002Freimbursement for travel not included)\n\nExclusion Criteria:\n\n* Peanut allergies or intolerances\n* Participants with \\>5% weight loss in the past 6 months or extreme dietary\u002Fphysical activity habits\n* An inability to follow the experimental intervention or to perform the required specimen collections.\n* Individuals with significant psychiatric or food disorders.\n* Current diagnosis, or history of cancer in past 3 years.\n* Current diagnosis or history of bone diseases, type I or II diabetes, gastrointestinal disease, hyperparathyroidism, untreated thyroid disease, significant immune, hepatic, cardiac, or renal disease.\n* Uncontrolled hypertension or hyperlipidemia in abnormal ranges.\n* History of surgery in the past 6 months or surgical procedure for weight loss in the past 3 years.\n* Regular use of medications that affect bone metabolism, including bisphosphonates or hormone replacement.\n* Regular use of medications for that affect the gastrointestinal tract including incretin mimetics, cholecystitis, urinary tract infection, severe organic diseases including coronary heart disease, myocardial infarction, infectious diseases including pulmonary tuberculosis and AIDS.\n* Antibiotic use in the past month\n* Alcohol or illicit drug abuse\n* Any other condition deemed by the Research Physician that would prevent participation in the study, e.g. participation in another clinical research project that may interfere with the results of this study.\n* Participation in another clinical interventional research trial","75 Years",{"count":276,"type":22},44,[25],"The aging population is rapidly increasing, and it is important to identify dietary factors that can prevent disease and promote health in this group. Legumes, such as peanuts, are a plant-based food high in protein and unsaturated fat making this a healthy choice but are not consumed frequently enough in older adults. Studies have shown that regular nut consumption is associated with lower adiposity and reduced weight gain, and several dietary pattern studies indicate that nuts and legumes are associated with better bone health. In addition, our preliminary translational data indicates that a higher monounsaturated fatty acid (MUFA) intake is associated with improved bone mineral density (BMD) and quality. Given these findings, the proposed study aims to examine the impact of consuming peanut products on bone health, metabolic health (e.g., serum glucose, insulin, lipids and inflammation), markers of brain and sleep health, and physical function in overweight and obese older adults before and after a six-month weight loss intervention using a randomized controlled design. The results of this study have the potential to provide valuable insights into the role of peanuts as a sources of fatty acids in promoting health and preventing disease in at-risk adults.",[280,281,30],"Weight Loss","Bone Density",[283,284,285,286,287,288,289,290],"weight loss","adults","bone","cognition","metabolic health","sleep","peanut","Monounsaturated fatty acid","2026-05-08",{"date":259,"type":38},{"date":294,"type":38},"2025-10-30",{"date":296,"type":22},"2027-12-31",{"name":298,"class":45},"Rutgers, The State University of New Jersey",{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":23,"phases":309,"briefSummary":310,"conditions":311,"keywords":312,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":46},"100565691","muscle-and-movement-with-anti-obesity-medications-100565691","NCT06645470","Muscle and Movement With Anti-Obesity Medications","Muscle Quantity and Quality, With and Without Exercise, Combined With Anti-Obesity Medications","M3","Inclusion Criteria:\n\n* Both males and females of all race\u002Fethnic groups are eligible for participation in this study.\n* Age: Randomized Study: Adults that are 18 to \\\u003C60 years of age. Observational Study: Adults that are \\>60 years of age.\n* Newly prescribed AOM (semaglutide, tirzepatide) for the treatment of obesity, approval for treatment (pharmacy, insurance, etc.), and the participant agreeing to start this treatment and continue treatment for at least 6 months (the participant will be recruited prior to this medication being initiated).\n* Body mass index (BMI) of \\>27.0 kg\u002Fm2 with at least one weight-related complication (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) provided it this does not compromise the ability to safely complete the screening or outcome measures or to engage in the prescribed exercise interventions), or \\>30 kg\u002Fm2 without weight-related complications. Enrollment will not be limited based on an upper BMI level provided that the participant meets the other eligibility requirements. However, weight or size limits of the dual-energy x-ray absorptiometry (DXA) system that is used to assess body composition must not be exceeded.\n* Ability to provide informed consent prior to participation in this study.\n* Clearance from the study physician for meeting all eligibility criteria for this study.\n\nExclusion Criteria:\n\n* Type 2 diabetes.\n* Report moderate-to-vigorous exercise for \\>60 min\u002Fweek, and \\>1 day of structured cardiovascular or resistance exercise over the past 3 months.\n* Report sustained weight loss of \\>3% in the past 3 months.\n* History of metabolic\u002Fbariatric surgery.\n* Females who are pregnant, pregnant within the past 6 months, or reporting a planned pregnancy during the study period.\n* Report a current medical condition or treatment for a medical condition that could affect body weight or contradict engagement in any aspect of the outcome measures or interventions.\n* History of muscle conditions that may impact the quality of muscle or response to the study interventions (e.g., myopathy, muscular dystrophy, rhabdomyolysis, etc.).\n* Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction or history of cardiomyopathy, coronary artery bypass grafting or angioplasty, conditions requiring chronic anticoagulation (i.e., recent or recurrent DVT).\n* Resting systolic blood pressure of \\>160 mmHg or resting diastolic blood pressure of \\>100 mmHg. If medicated for blood pressure control, the medication dose needs to be stable for \\>6 months.\n* Eating disorders that would contraindicate weight loss or physical activity.\n* Alcohol or substance abuse.\n* Current psychological condition that is untreated, hospitalization for a psychological condition within the past 12 months, or not being on a stable dose of treatment for at least 6 months.\n* Report plans to relocate to a location not accessible to the study site or having employment, personal, or travel commitments that prohibit attendance at scheduled intervention sessions or assessments.",{"count":308,"type":22},40,[25],"The goal of this clinical trial is to learn about changes in body composition related to obesity medication use, and whether aerobic or resistance exercise training will impact these body composition changes. It will also provide information about whether aerobic or resistance exercise training has additional benefits on other health and fitness measurements. The main questions it aims to answer are:\n\n* Is there a difference in the change in body composition (fat mass, lean mass, muscle mass, and bone content) between the standard medical care and the exercise conditions (aerobic training and resistance training)?\n* Is there a difference in the change in body weight and BMI between the standard medical care and the exercise conditions (aerobic training and resistance training)?\n* Is there a difference in the change in cardiorespiratory fitness between the standard medical care and the exercise conditions (aerobic training and resistance training)?\n* Is there a difference in how much physical activity is completed between the standard medical care and the exercise conditions (aerobic training and resistance training)?\n* Is there a difference in the change in physical function between the standard medical care and the exercise conditions (aerobic training and resistance training)?\n* Is there a difference in the change in muscle strength between the standard medical care and the exercise conditions (aerobic training and resistance training)?\n* Is there a difference in the change in resting blood pressure between the standard medical care and the exercise conditions (aerobic training and resistance training)?\n* Is there a difference in the change in food intake between the standard medical care and the exercise conditions (aerobic training and resistance training)?\n* Is there a difference in the change in health-related quality of life between the standard medical care and the exercise conditions (aerobic training and resistance training)?\n\nParticipants will:\n\n* Participate in an intervention for a period of 6 months that involves being assigned to a no exercise\u002Fstandard medical care condition, or a supervised exercise condition (aerobic training or resistance training).\n* Visit the clinical before starting the study and at 6 months to complete study measurements of their body composition and other measurements to monitor their progress.\n* Complete a brief monitoring session at weeks 6, 12, and 18 across the 6 months.\n* Complete supervised exercise sessions at the research center 3x per week for 6 months (Participants in the exercise groups only: aerobic training or resistance training).",[30],[258,283,313,254,314],"obesity medication","overweight","2026-05-07",{"date":317,"type":38},"2026-05-11",{"date":319,"type":38},"2024-12-01",{"date":321,"type":22},"2026-09",{"name":323,"class":45},"University of Kansas Medical Center",{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":138,"sex":18,"minAge":332,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":336,"briefSummary":337,"conditions":338,"keywords":339,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":354},"100582327","brain-and-behavior-influences-on-obesity-development-from-infancy-through-childhood-100582327","NCT06861868","Brain and Behavior Influences on Obesity Development From Infancy Through Childhood","Early Brain Development and Child Nutrition and Obesity","RESONATE","Inclusion Criteria:\n\n* Participants from the RESONANCE cohort are eligible if the participant will reach 7-12 years of age during the proposed project period and have no food allergies.\n\nExclusion Criteria:\n\n* Exclusion criteria for RESONANCE include:\n\n  1. In utero exposure to alcohol, cigarette, or illicit substances;\n  2. First trimester fetal US abnormalities;\n  3. Complicated pregnancy (e.g., pre-eclampsia);\n  4. Complicated delivery, including APGAR scores less than 8 and\u002For neonatal intensive care unit (NICU) admission;\n  5. History of neurological (e.g., epilepsy), psychiatric (e.g., anxiety or depression requiring treatment with medication) or developmental disorder (e.g., autism spectrum disorder (ASD), dyslexia);\n  6. Contraindications for MRI including metal in the body, claustrophobia.","7 Years","12 Years",{"count":335,"type":22},210,[25],"The investigators project, RESONATE, aims to investigate why some children develop obesity. To do this it uses data on eating and eating-related behaviors, genetic and environmental factors, and brain structure and function. This data is collected in a sub-sample of RESONANCE, a large study of families of children from infancy through childhood. The results will lay foundations for the development of early interventions to prevent or treat obesity.",[30],[254,314,340,341,342,343,344,345],"pediatric","eating behavior","appetite","neuroimaging","magnetic resonance imaging","brain development","2026-05-05",{"date":315,"type":38},{"date":349,"type":38},"2024-12-02",{"date":351,"type":22},"2029-03-31",{"name":353,"class":45},"Johns Hopkins University",4,{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":362,"enrollmentInfo":363,"targetDuration":4,"studyType":23,"phases":364,"briefSummary":365,"conditions":366,"keywords":372,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":46},"100568615","phase-2-palmitic-acid-and-human-microvascular-function-100568615","NCT06683534","Palmitic Acid and Human Microvascular Function","Use of Quercetin to Increase Resiliency to Palmitic Acid in the Human Microvasculature","Inclusion Criteria:\n\n* Obesity (BMI\\>30)\n* Aged 18-40 years\n* English Speaking\n\nExclusion Criteria:\n\n* BMI\\>60\n* Resting SBP ≥180 mmHg or DBP ≥ 110mmHg\n* Pregnancy or breastfeeding.\n* Prior history of myocardial infarction\n* Diagnosis of more than 1 risk factor for coronary artery disease (active smoker, diabetes mellitus- type 1 or 2, congestive heart failure, hyperlipidemia, hypertension)\n* Active mouth sores that affect the buccal mucosa.","40 Years",{"count":308,"type":22},[143],"The goal of this study is to learn how a supplement Quercetin can affect microvascular function.\n\nParticipants will:\n\n* give two blood draws of 5 mL each\n* have a camera placed under the tongue to take pictures of blood vessels\n* have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion\n\nResearchers will compare blood vessel function of those who take estrogen supplements to those who do not.",[367,368,369,370,371,30],"Microvascular Dysfunction","Microvasculature","Cardiovascular Diseases","Cardiovascular Diseases (CVD)","Microvascular Health",[64,373],"Supplement","2026-04-28",{"date":376,"type":38},"2026-04-29",{"date":378,"type":22},"2026-07",{"date":380,"type":22},"2030-12",{"name":382,"class":45},"Medical College of Wisconsin",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":23,"phases":393,"briefSummary":394,"conditions":395,"keywords":397,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":46},"100561288","effect-of-watermelon-on-gut-and-cardiometabolic-health-100561288","NCT06588218","Effect of Watermelon on Gut and Cardiometabolic Health","Effect of Daily Fresh Watermelon Consumption on Gut and Cardiometabolic Health in Young Adults With Overweight and Obesity","Inclusion Criteria:\n\n* Between 18 and 30 years old\n* Ability to speak and read in English\n* Overweight or Obese Class 1 and 2 (BMI ≥ 25 - 39.9 kg\u002Fm2)\n\nExclusion Criteria:\n\n* Intake of antibiotics in the last 3 months\n* Intake of pre\u002Fpro\u002Fpostbiotics in the last 3 months\n* Current or past (within the last 6 months) user of tobacco, marijuana, or E-cigarette products\n* Cardiovascular disease (will not exclude for hypertension), gastrointestinal disease (ulcerative colitis, celiac, Crohn's disease, diverticulosis, peptic ulcers, small intestinal bacterial overgrowth, short bowel syndrome), neurological (multiple sclerosis, meningitis, recent stroke) or endocrine disorders (uncontrolled thyroid disorders, growth hormone disorders, adrenal gland disorders, uncontrolled diabetes - A1C greater than 9%).\n* Food allergy to study foods\n* Any allergy to melon\n* Any allergy to the isocaloric snack (gluten)\n* Regular consumption of watermelon greater than 2 servings \u002F week\n* Current heavy alcohol use (≥ 15 drinks \u002F week for men, ≥ 8 drinks \u002F week for women\n* Class 3 Obesity (BMI \\> 40 kg\u002Fm2)\n* Current user of Citrulline, Arginine, Nitric Oxide or other supplements known to affect nitric oxide synthesis (beet root juice or any beet supplement, Pycnogenol \u002F Pine bark extract)\n* Known to be currently pregnant (self-disclosed)","30 Years",{"count":392,"type":22},36,[25],"The goal of this clinical trial is to evaluate the effect of daily fresh watermelon consumption for 6-weeks on gut health, including microbiome diversity, gut barrier and immune function in young adults with overweight and obesity. The main questions it aims to answer are:\n\n1. Will consuming fresh watermelon daily for 6-weeks will improve intestinal barrier health and increase microbiome diversity such as an increased population of beneficial 'probiotic' bacteria when compared to control participants consuming a low-fat snack?\n2. Will consuming fresh watermelon daily for six-weeks will improve other health measures, including body-composition, blood pressure, blood vessel function, blood lipid profiles, and measures of inflammation, as compared to control participants consuming a low-fat snack for the same time period?",[30,396],"Dysbiosis",[398,396,399,400,64,401,402,403,404,405],"Gut Microbiome","Diet","Overweight","Watermelon","Lycopene","Citrulline","Metagenomic","vascular","2026-04-08",{"date":408,"type":38},"2026-04-09",{"date":410,"type":38},"2024-10-13",{"date":412,"type":22},"2026-12",{"name":414,"class":45},"Florida State University",{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":138,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":422,"targetDuration":4,"studyType":23,"phases":424,"briefSummary":425,"conditions":426,"keywords":437,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":46},"100619127","implementation-facilitation-of-exercise-is-medicine-greenville-100619127","NCT07340580","Implementation Facilitation of Exercise is Medicine Greenville","Facilitating Health System Implementation of Physical Activity Screening and Referral to Community-Based Programs: Exercise is Medicine Greenville","The primary aim of this study is implementation facilitation at the clinic level. The secondary aim of this study is at the patient level. Therefore we have divided our inclusion\u002Fexclusion eligibility criteria by primary and secondary aim.\n\n1\\. Clinic (primary aim) Inclusion criteria\n\n* Currently EIMG-activated Prisma Health-Upstate Primary Care clinic (family or internal medicine)\n* Adopted EIMG \\>= 6 months prior to the beginning of this study\n\nExclusion criteria\n\n* Not EIMG-activated\n* Adopted EIMG \\\u003C 6 months prior to the beginning of this study\n* Greater than 15 miles from the nearest YMCA\n\n  1\\. Primary care clinic staff (primary aim) Inclusion criteria\n* At least 18 years of age\n* Has worked at the Prisma Health-Upstate clinic since the start date of the intervention in the respective wave, i.e., Pre-IF start date for each wave\n* Has clinical encounters with a minimum of 25 patients per month\n* Study clinic is their primary clinic (\\>50% of their working time)\n* Able to understand and communicate in English\n\nExclusion criteria\n\n* Less than 18 years of age\n* Work at the Prisma Health-Upstate clinic started after the Pre-IF phase began\n* Has clinical encounters with \\\u003C25 patients per month\n* Unable to speak or understand English\n* Adults unable to provide consent\n\n  2\\. Patient (secondary aim) Inclusion criteria (must meet all of below)\n* Age \\>= 18 and \\\u003C= 80 years\n* Clinically eligible (diagnosis of hypertension, dyslipidemia, obesity, diabetes, or physical inactivity) to receive an EIMG referral\n* A healthcare visit with an eligible encounter type (evaluation, telemedicine, consult, office visit, e-visit, follow-up, appointment, education, multidisciplinary visit, nutrition, occupational medicine-office visit)\n* A healthcare visit at a participating clinic\n\nExclusion criteria\n\n* Age \\\u003C 18 or \\> 80 years\n* Current referral to Physical therapy or occupational therapy\n* Current referral to cardiac, pulmonary, or oncology rehab\n* One of the following visit diagnoses listed below:\n\n  * Alzheimer's disease\n  * Amyotrophic lateral sclerosis\n  * angina or chest pain\n  * congenital stenosis of aortic valve\n  * congenital insufficiency of aortic valve\n  * moderate or severe persistent asthma\n  * typical or atypical atrial flutter\n  * autonomic dysreflexia\n  * acute bronchitis\n  * cerebral infarction\n  * encounter for chemotherapy\n  * chronic kidney disease (stage 3-5)\n  * end stage renal disease\n  * coma\n  * acute chronic obstructive pulmonary disease\n  * unspecified dementia\n  * dependence on renal dialysis\n  * trisomy 21\n  * pulmonary embolism\n  * venous embolism and thrombosis\n  * history of falling\n  * acute fracture\n  * left ventricular failure\n  * congestive heart failure\n  * hypertensive urgency, emergency or crisis\n  * diabetes with ketoacidosis\n  * chronic respiratory failure\n  * dependence on supplemental oxygen\n  * myocardial infarction\n  * osteoporosis with current fracture\n  * encounter for palliative care\n  * paraplegia or quadriplegia\n  * Parkinson disease\n  * pneumonia\n  * encounter for supervision of pregnancy\n  * encounter for radiation therapy\n  * serious mental illness (schizophrenia, psychotic disorder)\n  * homicidal or suicidal ideations\n  * sepsis\n  * injury of spinal cord\n  * presence of coronary stent\n  * dependence on wheelchair or ambulatory aid\n\nFor patients completing accelerometry data collection, the additional inclusion\u002Fexclusion criteria apply:\n\nInclusion criteria:\n\n* Received an EIMG referral and scheduled for orientation\n* Attending orientation at two pre-determined community PA facilities (these sites were selected due to each being the largest urban and rural YMCA referral sites in the study)\n\nExclusion criteria:\n\n* Unable to provide verbal informed consent\n* Planning on travel or vacation during data collection, as patient PA behavior is anticipated to differ from 'everyday' PA behavior at home\n* Unable to wear a watch during work hours due to employment restrictions e.g., food service, healthcare, operating heavy machinery\u002Fconstruction, laboratory-based work etc.\n\nIn addition, for patients completing interviews, the additional inclusion\u002Fexclusion criteria apply:\n\nInclusion criteria:\n\n\\- Received an EIMG referral\n\nExclusion criteria:\n\n* Unable to provide verbal informed consent\n* Unable to speak or understand English\n* \\\u003C18 years of age",{"count":423,"type":22},35,[25],"A public health priority exists for the U.S. healthcare sector to integrate physical activity (PA) as a part of the patient care model. This research will provide valuable information on facilitating optimal implementation of a clinic-to-community model that identifies, refers, and enrolls physically inactive patients to community-based PA programs for the prevention and treatment of chronic diseases. Further, this work will provide evidence on the cost-effectiveness of integrating PA in healthcare systems as a population health management strategy.",[427,428,30,429,430,431,432,433,434,435,436],"Physical Inactivity","Dyslipidemia","Hypertension","Diabetes","Health Care Delivery","Patients","Chronic Disease","Exercise","Physical Activity","Implementation Science",[438,439,440,441,442],"Implementation Facilitation","Physical activity referral scheme","Effectiveness-implementation hybrid type 3","Pragmatic design","Stepped wedge","2026-03-27",{"date":445,"type":38},"2026-04-02",{"date":447,"type":22},"2026-05-01",{"date":449,"type":22},"2030-07-31",{"name":451,"class":45},"University of South Carolina",{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":18,"minAge":459,"maxAge":460,"enrollmentInfo":461,"targetDuration":4,"studyType":23,"phases":463,"briefSummary":464,"conditions":465,"keywords":466,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":479},"100572359","phase-2-safety-and-efficacy-of-na-931-and-tirzepatide-in-adults-who-are-overweight-or-obese-100572359","NCT06732245","Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese","A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women","Inclusion Criteria:\n\n* A written informed consent must be obtained before any study-related assessments are performed.\n* Men and women between 18 and 80 years, inclusive; women of child-bearing potential (defined as those who are not post-menopausal or post-surgical sterilization) must meet both of the following criteria:\n\n  * Two negative pregnancy tests (at screening and at randomization, prior to dosing)\n  * Use of intrauterine device, from at least 3 months before the baseline visit through at least 4 months after the last dose of NA-931\u002Fplacebo oral, and an additional contraceptive (barrier) method from screening through at least 4 months after the last dose of NA-931\u002Fplacebo oral.\n* Body mass index (BMI) ≥ 30 or BMI ≥ 27 with one or more obesity-associated comorbidities (e.g., hypertension, insulin resistance, sleep apnea, or dyslipidemia)\n* Stable body weight (± 5 kg) within 90 days of screening, and body weight \\\u003C150 kg\n* Have a history of at least one self-reported unsuccessful behavioral effort to lose body weight\n* Able to communicate well with the Investigator, comply with the study requirements and adhere to the diet and activity programs for the study duration\n\nExclusion Criteria:\n\n* • History of, or known hypersensitivity to, monoclonal antibody drugs or a contraindication to Tirzepatide (Zepbound® or Mounjaro®)\n\n  * Use of other investigational drugs at the time of enrollment or within 30 days or 5 half-lives of enrollment, whichever is longer, or longer if required by local regulations\n  * Treatment with any medication for the indication of obesity within the past 30 days before screening\n  * Diagnosis of diabetes requiring current use of any antidiabetic drug or HbA1c ≥ 6.5% Note: Metabolic syndrome is not an exclusion, even if managed with an anti-diabetic drug such as metformin or an SGLT2 inhibitor. A diagnosis of prediabetes or impaired glucose tolerance managed exclusively with non-pharmacologic approaches (e.g., diet and exercise) is not an exclusion.\n  * Any chronic infections likely to interfere with study conduct or interpretation such as hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV). History of hepatitis A or hepatitis C successfully treated is not exclusionary. Active COVID-19 infection.\n  * Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing, or longer if required by local regulation, or plasma donation (\\> 250 mL) within 14 days prior to the first dose\n  * Any disorder, unwillingness, or inability not covered by any of the other exclusion criteria, which in the Investigator's opinion, might jeopardize the participant's safety or compliance with the protocol","19 Years","80 Years",{"count":462,"type":22},224,[143],"A phase 2 study to assess the efficacy of NA-931 alone or in addition to Tirzepatide to assess efficacy and safety in overweight or obese men and women",[30],[467,64,468,314,469,470],"NA-931","Biomed Industries, Inc","Tirzepatide","Zepbound","2026-03-24",{"date":443,"type":38},{"date":474,"type":22},"2026-08-15",{"date":476,"type":22},"2027-12-15",{"name":478,"class":100},"Biomed Industries, Inc.",17,{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":18,"minAge":390,"maxAge":139,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":490,"briefSummary":491,"conditions":492,"keywords":494,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":46},"100582024","improving-health-and-reducing-chronic-disease-risk-in-middle-aged-adults-through-nutrition-100582024","NCT06857929","\"Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition\"","Nutritional Approach for the Transformation and Reduction of Chronic Disease Indicators in Middle-aged Adults at High Risk","NUTRI-M-Care","Inclusion Criteria:\n\n* BMI 27-40 Kg\u002Fm2\n* Metabolic syndrome according to International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity\n* Stable weight in the last 3 months (weight changes \\\u003C 4Kg)\n* Be able to give informed consent\n\nExclusion Criteria:\n\n* Have a diagnosed illness that interferes with the recommendations proposed in the intervention.\n* Women with established menopause.\n* Pregnant or breastfeeding women.\n* Serious psychiatric illness\u002Fdisorder.\n* Social, cultural or psychological factors that may affect adherence to the intervention protocol.\n* Inability to communicate with study staff.\n* Inability to follow recommended diet or inability to engage in physical activity.\n* Low likelihood of modifying dietary habits according to the different stages of change according to the Prochaska and DiClemente model.\n* Difficulty attending scheduled appointments within the intervention due to work schedule conflicts, travel plans, scheduled surgeries, among other reasons.\n* Therapeutic non-compliance.\n* Participating in a professionally-led nutritional intervention.\n* Being under medical treatment that affects weight, intake or energy expenditure in the 3 months preceding the start of the study.\n\nSmokers who have changed their smoking habit in the 6 months preceding the start of the study (including starting or stopping smoking).\n\n\\- Participation in another trial that may interfere with this proposed study.",{"count":489,"type":22},106,[25],"The goal of this clinical trial is to evaluate the effect of a multifactorial lifestyle intervention combining Mediterranean diet, energy reduction and physical activity on weight loss in middle-aged adults (men and women 30-50 years old) with metabolic syndrome. The main questions it aims to answer are:\n\nIs a multifactorial intervention based on Mediterranean diet, energy reduction and physical activity able to promote weight loss maintenance in middle-aged men and women with metabolic syndrome? syndrome? Which are the sociodemographic barriers to adhere to a multifactorial lifestyle intervention to promote cardiometabolic health? How is the lifestyle pattern of middle-aged Spanish adults with metabolic\n\nResearchers will compare a multifactorial lifestyle intervention combining Mediterranean diet, energy reduction and physical activity to a control intervention based on usual primary healthcare to see if the intervention improve cardiometabolic traits and promote weight loss maintenance after 1 year.\n\nParticipants in the intervention arm will be asked to follow an energy-reduced Mediterranean diet plus a physical activity program with the aim of reducing 5-10% of the initial weight in 6 months and of maintaining the weight lost after 1 year o follow-up.",[493,197,30],"Metabolic Syndrome",[495,496,497,498,499,500,256],"metabolic syndrome","Mediterranean diet","Caloric restriction","Physical activity","Weight loss","Weight","2026-03-23",{"date":443,"type":38},{"date":504,"type":38},"2026-03-01",{"date":506,"type":22},"2028-09-30",{"name":508,"class":45},"IMDEA Food",{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":138,"sex":516,"minAge":19,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":23,"phases":519,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":354},"100571739","chime-comparing-health-interventions-for-maternal-equity-100571739","NCT06724172","CHIME: Comparing Health Interventions for Maternal Equity","CHIME","Inclusion Criteria:\n\n* Maternal age 18 years or older\n* Maternal gestational age ≤ 20 weeks with viable singleton pregnancy documented on first trimester ultrasound with an intention to continue pregnancy to term\n* Plans to continue receiving antenatal care at the recruitment site\u002Fnetwork\n* Maternal characteristics include at least one of the following:\n* Self identifies as Black\u002FAfrican American\n* Self identifies as Hispanic\u002FLatino\u002Fa\u002Fe\u002Fx\n* Insured by Medicaid\n* Maternal ability to speak English or Spanish\n* Completion of baseline data collection (maternal survey data, weight, and height measurement prior to randomization)\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years at baseline because of unique developmental differences of adolescents and regulations regarding age of consent\n* Underweight (BMI \\\u003C18 kg\u002Fm2) at pre-pregnancy period\n* Underlying disease\u002Ftreatment that might impact weight status (e.g., significant gastrointestinal conditions, major psychiatric disorders, and others at the discretion of the study clinician)\n* Unwillingness or inability to complete study visits or intervention components\n* Unwillingness or inability to commit to intervention components for self or infant, including plans to move more than 100-mile radius from recruitment site\n* Multiple gestations","FEMALE",{"count":518,"type":22},795,[25],"The goal of this comparative effectiveness trial is to compare how three different approaches to overcome barriers to resources and provide nutrition and physical activity counseling improve maternal healthy weight in pregnancy and postpartum.\n\nThe main question it aims to answer is which of the two multi-level, multi-component interventions has greater effectiveness in reducing maternal postpartum weight retention at 12-months postpartum.\n\nHypothesis (primary): Both multi-level, multi-component interventions will have greater effectiveness reducing maternal postpartum weight retention at 12-months postpartum than the usual care group.\n\nHypothesis (secondary): The community-based intervention will have greater effectiveness than the self-management intervention.\n\nParticipants will be asked to participate in one of the study interventions from early pregnancy until 12 months postpartum and complete five research visits. General procedures include completion of:\n\n* Questionnaires\n* Dietary recalls\n* In-depth interviews\n* Anthropometric measurements\n* Collection of blood via finger stick or blood panel",[30,522,433,430,523],"Nutrition","Pregnancy","2026-03-03",{"date":526,"type":38},"2026-03-05",{"date":528,"type":38},"2026-01-22",{"date":530,"type":22},"2030-04-01",{"name":532,"class":45},"Stanford University",{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":12,"sex":18,"minAge":540,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":23,"phases":543,"briefSummary":544,"conditions":545,"keywords":549,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":46},"100564015","phase-2-a-mobile-intervention-to-reduce-pain-and-improve-health-iii-100564015","NCT06623669","A Mobile Intervention to Reduce Pain and Improve Health-III","MORPH-III","Inclusion Criteria:\n\n* Aged 65+ years\n* Body mass index of 30-45 kg\u002Fm2 or \\>45 kg\u002Fm2 with physician's approval\n* No loss or gain of more than 5% body mass in previous 6 months\n* Presence of knee or hip osteoarthritis as ascertained via the Roux questionnaire\n* Independently living\n* Low active (i.e., not participating in regular resistance training and\u002For \\>20 mins\u002Fday of aerobic exercise on more than 2 days\u002Fweek in past 3 months as ascertained via a modified CHAMPS questionnaire)\n* Have no contraindication for safe and optimal participation in exercise based on EASY screening (pertaining to chest pain and discomfort during physical activity, dizziness or light headedness, or frequent falls and use of assistive devices)\n* Not currently using a weight loss medication (medications for diabetes management are permitted if weight stable)\n* Approved for participation by medical director\n* Willing to provide informed consent and agree to all study procedures and assessments.\n\nExclusion Criteria:\n\n* Reside in skilled nursing facility, rehab or assisted living environment\n* History of pharmacologic treatment for a psychiatric disorder other than depression\u002Fanxiety within past year\n* Current untreated and\u002For unstable clinical depression or anxiety (Patient Health Questionnaire (PHQ-9) \\>15)\n* Hospitalization for psychiatric event within past year prior to screening\n* History of mild cognitive impairment or dementia\n* Cognitive impairment (\\\u003C32) on Modified Telephone Interview for Cognitive Status survey (TICS-M)\n* Hearing or visual impairment that would preclude use of the videoconferencing software\n* Severe arthritis or other musculoskeletal disorder that is a contraindication for safe walking\n* Presently undergoing treatment for orthopedic fracture\n* Currently using a weight loss medication (medications for diabetes management are permitted if weight stable)\n* Contraindication based on EASY screening (pertaining to chest pain and discomfort during physical activity, dizziness or light headedness, or frequent falls and use of assistive devices) without physician approval\n* Joint replacement or other orthopedic surgery in past 6 months\n* Joint replacement or other orthopedic surgery planned in next 18 months\n* Have a diagnosis of uncontrolled hypertension; current or recent past (within 1 year) severe symptomatic heart disease, uncontrolled angina, stroke, chronic respiratory disease other than asthma or COPD, any disease requiring oxygen use, neurological or hematological disease; cancer requiring current treatment, except non-melanoma skin cancers; kidney failure requiring dialysis; have a Katz ADL disability; or engage in heavy alcohol use \\>14 drinks\u002Fweek.\n* Current participation in other research study with a prospective intervention\n* Unable\u002Funwilling to commit to study protocol, including random assignment and use of technology tools\n* Unable\u002Funwilling to attend three virtual testing appointments","65 Years",{"count":542,"type":22},200,[143],"The experience of chronic pain powerfully and negatively affects quality of life and functional independence in aging. Unfortunately, while as many as three in four older adults experience chronic pain, few have access to effective non-pharmacological pain management strategies. Participating in regular physical activity, avoiding sustained sitting, and maintaining a healthy weight are important and interrelated lifestyle inputs to chronic pain, and socially rich behavioral interventions informed by contemporary theories of behavior change appear important for engaging in activity and healthy eating in the long term. Our group has demonstrated in a series of Stage I trials that a group-mediated behavioral intervention combining dietary behavior change and a physical activity program focused on moving often throughout the day contributes to meaningful weight loss, and lasting weight maintenance, with pilot data suggesting this may contribute to improved pain, physical function, and health-related quality of life among older adults with chronic pain. As these were NIH Stage I trials, there are several important gaps to be addressed in the present trial: (1) both studies of chronic pain recruited small samples and were 12 weeks in duration, limiting our ability to establish efficacy and the durability of changes to activity, HRQOL, and pain outcomes; (2) participants included anyone with chronic pain, regardless of pain type, a likely contributor to heterogeneous pain intensity and interference findings; and (3) the investigators have yet to examine behavioral maintenance.\n\nThe overarching goal of the proposed Stage II \"mobile intervention to reduce pain and improve health-III (MORPH-III)\" is to establish the efficacy of the intervention for enhancing physical activity via steps (primary), and for reducing pain interference and body weight while enhancing physical function (secondary) among older adults with chronic knee or hip osteoarthritic (OA) pain. The investigators will recruit 200 older adults with knee or hip osteoarthritic pain to engage in a 6-month remotely delivered intervention comprising weekly group or individual intervention meetings plus brief individual goal-setting coaching calls. This will be followed by a 12-month no-contact maintenance period, where participants will attempt to sustain behavioral goals on their own.\n\nThe Specific Aims are:\n\nSpecific Aim 1: To examine the impact of MORPH on ActivPAL-assessed daily steps relative to an enhanced usual care control. Hypotheses: MORPH will significantly increase steps relative to control at month 6.\n\nSpecific Aim 2: To examine the impact of MORPH on pain interference, change in body weight, and physical function relative to the enhanced usual care control. Hypotheses: MORPH will result in significant reductions in pain interference and body weight and improvement in physical function relative to control at month 6.\n\nExploratory Aims: Aim 1: To investigate the impact of the MORPH intervention on steps, weight change, pain interference, and physical function at month 18. Aim 2: If the MORPH intervention results in reduced pain interference at 6 and\u002For 18 months, the investigators will examine the extent to which 6-month change in steps, weight, pain self-efficacy, and catastrophizing mediate change in interference at 6 and\u002For 18 months.",[546,547,30,548],"Chronic Pain","Osteoarthritis","Inactivity",[550,551,435,280,552],"Digital health","Randomized Trial","Aging","2026-02-18",{"date":555,"type":38},"2026-02-20",{"date":557,"type":38},"2025-08-14",{"date":559,"type":22},"2029-08-31",{"name":561,"class":45},"Wake Forest University",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":18,"minAge":570,"maxAge":571,"enrollmentInfo":572,"targetDuration":4,"studyType":23,"phases":574,"briefSummary":575,"conditions":576,"keywords":578,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":46},"100575172","new-mechanisms-of-obesity-100575172","NCT06768827","New Mechanisms of Obesity","Pathogenic Mechanisms of Obesity and Its Cardiometabolic Complications","NMoO","Inclusion Criteria:\n\n* Age 15 to 22 years\n* In puberty (girls and boys: Tanner stage III-V);\n* BMI \\>85th\n\nExclusion Criteria:\n\n* Pregnancy;\n* endocrinopathies (e.g., Cushing syndrome);\n* substance abuse;\n* medications affecting insulin resistance such as metformin, GLP-1 analogues; -\n* high fibers intake (\\> 30g\u002Fday) as assessed by a 3-day food record.","15 Years","22 Years",{"count":573,"type":22},55,[25],"Given the pervasiveness of Pediatric Obesity, it is imperative to understand its pathophysiology and develop alternative strategies to reverse this condition. Herein, investigators propose to elucidate the interaction between colonic fermentation and insulin resistance in modulating metabolism in youth with obesity.",[30,577,198],"Insulin Resistance",[64,579,577,580],"Youth","Intestinal Fermentation","2026-01-26",{"date":583,"type":38},"2026-01-28",{"date":585,"type":38},"2025-11-13",{"date":587,"type":22},"2030-03-31",{"name":589,"class":45},"Yale University",{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":596,"eligibilityCriteria":597,"healthyVolunteers":12,"sex":516,"minAge":221,"maxAge":598,"enrollmentInfo":599,"targetDuration":4,"studyType":23,"phases":601,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":612,"locationsCount":46},"100581859","time-restricted-eating-in-menopause-and-hormone-sensitive-breast-cancers-tremho-100581859","NCT06855784","Time-Restricted Eating in Menopause and HOrmone-sensitive Breast Cancers (TREMHO)","Time-Restricted Eating to Improve Body Composition and Symptoms in Menopause and HOrmone-sensitive Breast Cancers (TREMHO) - An Open-label Randomized Controlled Trial","TREMHO","Inclusion Criteria:\n\n* Women with confirmed physiological menopause without current anti-cancer treatment (group A), or women with menopausal symptoms in the context of aromatase inhibitors used as adjuvant therapy for hormone-sensitive non-metastatic breast cancers regardless of physiological menopause before the cancer diagnosis (group B)\n* Age 40-65 years\n* Body mass index 25-40 kg\u002Fm2\n* Stable weight (± 2 kg) over the previous month\n* Eating window ≥ 12 hours (self-reported and measured during the run-in phase)\n* Able to give informed consent and follow the study procedures for the entire duration\n* Confident use of a smartphone and able to take regular pictures of food\u002Fdrinks\n\nExclusion Criteria:\n\n* On a hypocaloric restrictive diet, intermittent fasting or in a weight management program over the previous month\n* Previous bariatric surgery or planned during the study\n* Active eating disorder(s) or major mental illness at inclusion\n* Psychoactive treatment with recent or planned changes of drug compound or dosage\n* Treatments affecting body weight (e.g. glucocorticoids, GLP-1 receptor analogues)\n* Diabetes with hypoglycemic drug(s) will be excluded, however those with prediabetes (as defined by the American Diabetes Association) or diabetes with no risk of hypoglycemia (i.e. treated with non-hypoglycemic drugs or without medication) will be included\n* Active metabolic bone diseases (e.g. Paget disease, osteomalacia), however women with osteoporosis will be included\n* Shift work comprising night shifts (working between 11pm and 6am) over the previous 2 weeks or planned during the study\n* Travel\u002Ftrip to a different time zone (≥ 2-hour time difference) over the previous 2 weeks or planned during the study\n* Enrolled in another interventional clinical trial (medication, surgery, medical device) over the previous 2 weeks or planned during the study","60 Years",{"count":600,"type":22},84,[25],"This study is aimed at women currently going through menopause, either as part of the natural process (physiological menopause), or following hormonal treatment for breast cancer. There are several ways of slowing the weight gain frequently encountered in this situation, reducing the intensity of menopause-related symptoms and improving quality of life in this context.\n\nIn this trial, the investigators examine the efficacy and possible adverse effects of intermittent fasting compared with a control intervention. Participation lasts 14 weeks, with an optional 12-month follow-up. Study participants are randomly assigned to either the intervention group or the control group. In the intervention group, study participants fast for 16 hours per day and eat over a period of 8 hours (intermittent fasting often called time-restricted eating \\[TRE\\] 16h\u002F8h). In the control group, the usual eating pattern is continued for 12 weeks.\n\nThe main objective of the study is to evaluate the efficacy of TRE in terms of weight and fat loss, improvement in metabolic profile, menopausal symptoms and bone health. In addition, the study team closely monitors any adverse effects.",[604,30],"Menopause","2026-01-23",{"date":607,"type":38},"2026-01-27",{"date":609,"type":38},"2025-04-30",{"date":611,"type":22},"2027-03-01",{"name":613,"class":45},"University Hospital, Geneva",{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":618,"acronym":619,"eligibilityCriteria":620,"healthyVolunteers":138,"sex":18,"minAge":362,"maxAge":274,"enrollmentInfo":621,"targetDuration":4,"studyType":23,"phases":623,"briefSummary":624,"conditions":625,"keywords":628,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":638,"lastUpdatePostDateStruct":639,"startDateStruct":641,"completionDateStruct":643,"leadSponsor":645,"locationsCount":241},"100587073","targeted-precision-nutrition-strategy-to-prevent-chronic-metabolic-diseases-100587073","NCT06923644","Targeted Precision Nutrition Strategy To Prevent Chronic Metabolic Diseases","PRECINUT","Inclusion Criteria:\n\n* Men and women with a BMI ≥25 to \\\u003C40 kg\u002Fm2\n* Classification possible to one of the investigational metabolic phenotypes according to the classification algorithm.\n* Weight stability for at least 3 months (+\u002F- 3 kg)\n\nExclusion Criteria:\n\nDiseases\n\n* (Pre-)diagnosis of type 1 or type 2 diabetes mellitus (i.e., FPG ≥ 7,0 mmol\u002FL) and HbA1c ≥ 6,5% (48 mmol\u002Fmol)\n* Renal or hepatic malfunctioning (pre-diagnosis or determined based on ALAT and creatinine values)\n* Gastrointestinal diseases or abdominal surgery (allowed i.e.:\n\nappendectomy, cholecystectomy)\n\n* Food allergies, intolerances (including gluten\u002Flactose intolerance) and\u002For eating disorders interfering with the study\n* Cardiovascular diseases (e.g., heart failure) or cancer (e.g., noninvasive skin cancer allowed)\n* High systolic blood pressure (untreated \\>160\u002F100 mmHg, drug-regulated \\>140\u002F90 mmHg)\n* Diseases affecting glucose and\u002For lipid metabolism (e.g., pheochromocytoma, Cushing's syndrome, acromegaly)\n* Diseases with a life expectation shorter than 5 years\n* Major mental disorders\n* Drug treated thyroid diseases (well substituted hypothyroidism is allowed inclusion)\n* Other physical\u002Fmental conditions that may interfere with study outcomes\n\nMedication\n\n* Medication known to interfere with study outcomes (e.g., PPAR-α or PPAR-γ agonists (fibrates), sulfonylureas, biguanides, α-glucosidaseinhibitors, thiazolidinediones, repaglinide, nateglinide, insulin, and chronic use of NSAIDs)\n* Use of certain anticoagulants other than acetylsalicylic acid\n* Use of antidepressants (stable use ≥ 3 months prior to and during study allowed)\n* Use of statins (stable use ≥ 3 months prior to and during study allowed)\n* Chronic corticosteroids treatment (\\>7 consecutive days of treatment)\n* Use of antibiotics within 3 months prior to the study\n\nLifestyle\n\n* Participation in regular sports activities (moderate-to-vigorous physical exercise \\>4 hours per week)\n* Having a restricted dietary pattern interfering with the study diets (e.g., vegetarian, vegan, Atkins diet and\u002For other special diets)\n* Plans to lose or gain more than 5% body weight\n* Abuse of alcohol (alcohol consumption \\>14 units\u002Fweek) and\u002For drugs (cannabis included)\n* Not willing to limit alcohol consumption to 7 drinks per week\n* Regular smoking (including use of e-cigarettes and vapes)\n* Use of strong vitamins or other dietary supplements (e.g., pre- or probiotics) expected to interfere with the study outcomes\n\nOther\n\n* Metabotype classification is not possible\n* Pregnant or lactating women, or women who are planning to become pregnant\n* Inability to comply with the study diet\n* Blood donation within the last 3 months\n* Participation in possibly interfering studies within the last 3 months\n* Inability to understand study information and\u002For communicate with staff\n* Unwillingness to be randomised or sign informed consent\n* Unwillingness to save data for 15 years\n* Deemed unsuitable for participation in the trial, for any reason, as judged by the research physician or principal investigator",{"count":622,"type":22},240,[25],"Nutrition is very important to keep blood sugar levels balanced. If blood sugar levels are too high, it can lead to diseases such as cardiovascular disease and type 2 diabetes (T2DM). Therefore, adjusting what one eats, also called a diet or nutritional intervention, can help prevent these diseases. However, not everyone responds the same to a diet. In about 30% of people, a diet does not work as hoped. This can be due to various reasons, such as a person's metabolism, genetic predisposition, the composition of the food one eats, or the bacteria in the intestines. Everyday things like sleep, stress, and movement also play a role. The investigators used a computer model to classify people with overweight and obesity into groups based on these factors. The investigators call such a group a 'Metabolic Phenotype', or in short 'Metabotype'. Based on the Metabotype, a personalised diet was developed (personalised nutrition intervention) that may better suit each person's unique situation.\n\nThe investigators hypothesize that a precision nutrition intervention, tailored to Metabotypes identified through unsupervised clustering (using the aforementioned computer model) of predefined, accurate features related to cardiometabolic health-specifically, tissue-specific glucose and lipid metabolism and detailed body composition-will enhance blood glucose homeostasis, reduce cardiometabolic risk, and improve adherence to the intervention and mental well-being, compared to population-based dietary guidelines. The present project will contribute to targeted and efficient precision-based dietary strategies for individuals at increased risk of T2DM.",[30,626,627],"Pre-diabetic","Type 2 Diabetes Mellitus (T2DM)",[629,630,631,632,633,634,635,636,637],"Dietary intervention trial","Precision nutrition","Tissue-specific insulin resistance","Body composition","Metabotyping","Glucose homeostasis","Cardiometabolic health","Insulin resistance","Metabolic phenotype","2026-01-15",{"date":640,"type":38},"2026-01-20",{"date":642,"type":38},"2025-04-23",{"date":644,"type":22},"2027-04",{"name":646,"class":45},"Maastricht University Medical Center",{"id":648,"slug":649,"hasResults":12,"nctId":650,"briefTitle":651,"officialTitle":652,"acronym":4,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":654,"targetDuration":4,"studyType":23,"phases":656,"briefSummary":657,"conditions":658,"keywords":659,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":663,"startDateStruct":665,"completionDateStruct":667,"leadSponsor":669,"locationsCount":46},"100565022","comparision-of-aerobic-exercise-to-aerobic-plus-yoga-exercise-for-weight-loss-in-adults-with-overweight-or-obesity-100565022","NCT06636773","Comparision of Aerobic Exercise to Aerobic Plus Yoga Exercise for Weight Loss in Adults With Overweight or Obesity.","Effectiveness of the Addition of Yoga to a Behavioral Weight Loss Intervention for Adults With Overweight or Obesity (MOVE for Health)","Inclusion Criteria:\n\n* Both males and females of all race\u002Fethnic groups are eligible for participation in this study.\n* at least 18 years of age. The investigators will not limit enrollment based on an upper age provided that the participant meets the other eligibility requirements.\n* Body mass index (BMI) of at least 25.0 kg\u002Fm2. The investigators will not limit enrollment based on an upper BMI level provided that the participant meets the other eligibility requirements. However, maximal weight to be eligible will be 350 pounds to meet the weight requirements for the equipment that will be used in this study.\n* Ability to provide informed consent prior to participation in this study.\n* Ability to provide clearance from their primary care physician to engage in the diet and physical activity components of the weight loss intervention.\n\nExclusion Criteria:\n\n* Report moderate-to-vigorous exercise on \\>3 days\u002Fweek or a total of \\>60 min\u002Fweek over the past 3 months.\n* Engaging in any style of yoga on an average of at least 1 day\u002Fweek over the past 3 months.\n* Report weight loss of 3% or more or participating in a weight reduction diet in the past 3 months.\n* Currently prescribed an anti-obesity medication.\n* Females who are pregnant or breastfeeding or reporting a planned pregnancy during the study period.\n* History of bariatric surgery.\n* Report a current medical condition or treatment for a medical condition that could affect body weight.\n* Current congestive heart failure, angina, uncontrolled arrhythmia, symptoms indicative of an increased acute risk for a cardiovascular event, prior myocardial infarction, coronary artery bypass grafting or angioplasty, conditions requiring chronic anticoagulation (i.e., recent or recurrent DVT).\n* Resting systolic blood pressure of 160 mmHg or more or resting diastolic blood pressure of 100 mmHg or more. If medicated for blood pressure control, the medication dose needs to be stable for at least 6 months.\n* Eating disorders that would contraindicate weight loss or physical activity.\n* Alcohol or substance abuse.\n* Current psychological condition that is untreated, hospitalization for a psychological condition within the past 12 months, or not being on a stable dose of treatment for at least 6 months.\n* Report plans to relocate to a location not accessible to the study site or having employment, personal, or travel commitments that prohibit attendance at scheduled intervention sessions or assessments.",{"count":655,"type":22},290,[25],"The goal of this clinical trial is to learn whether adding yoga exercise to a behavioral weight loss intervention improves weight loss in adults with overweight or obesity. It will also provide information about whether this approach to weight loss has additional benefits on other health and fitness measurements. The main questions it aims to answer are:\n\n* Is there a difference in weight loss between the behavioral program that includes aerobic exercise plus yoga compared to the behavioral program that includes only aerobic exercise?\n* Is there a difference in how much physical activity is completed between the behavioral program that includes aerobic exercise plus yoga compared to the behavioral program that includes only aerobic exercise?\n* Is there a difference in the change in body composition (fat mass, lean body mass) between the behavioral program that includes aerobic exercise plus yoga compared to the behavioral program that includes only aerobic exercise?\n* Is there a difference in the change in cardiorespiratory fitness the behavioral program that includes aerobic exercise plus yoga compared to the behavioral program that includes only aerobic exercise?\n* Is there a difference in the change in muscle strength between the behavioral program that includes aerobic exercise plus yoga compared to the behavioral program that includes only aerobic exercise?\n* Is there a difference in the change in resting blood pressure between the behavioral program that includes aerobic exercise plus yoga compared to the behavioral program that includes only aerobic exercise?\n* Is there a difference in the change in food intake or eating behaviors between the behavioral program that includes aerobic exercise plus yoga compared to the behavioral program that includes only aerobic exercise?\n* Is there a difference in the change in feelings of stress or mood between the behavioral program that includes aerobic exercise plus yoga compared to the behavioral program that includes only aerobic exercise?\n* Is there a difference in the change in sleep between the behavioral program that includes aerobic exercise plus yoga compared to the behavioral program that includes only aerobic exercise?\n* Is there a difference in the change in mindfulness between the behavioral program that includes aerobic exercise plus yoga compared to the behavioral program that includes only aerobic exercise?\n\nParticipants will:\n\n* Participate in a weight loss program for a period of 12 months that involves attending behavioral weight loss sessions. This involves coming to a session at the research center weekly for the initial 6 months and then every other week for the remaining 6 months.\n* Attempt to reduce the amount of food that they eat to reduce the calories they consume.\n* Participate in a combination of aerobic exercise plus yoga or just aerobic exercise.\n* Keep a record of the food they consume, use a digital scale provided to them, and wear an activity tracker provided to them for the period of 12 months.\n* Visit the clinical before starting the weight loss program, after 3 months, 6 months, 9 months, and 12 months to complete measurements of their weight and other measurements to monitor their progress.\n* Complete exercise sessions in the clinic between weeks 2-6, at month 6, and at month 12 to provide information about how they response to a single session of exercise.",[30],[254,314,258,660,661,283],"physical activity","yoga","2026-01-07",{"date":664,"type":38},"2026-01-09",{"date":666,"type":38},"2025-01-03",{"date":668,"type":22},"2029-02-28",{"name":323,"class":45},{"id":671,"slug":672,"hasResults":12,"nctId":673,"briefTitle":674,"officialTitle":675,"acronym":4,"eligibilityCriteria":676,"healthyVolunteers":12,"sex":516,"minAge":4,"maxAge":4,"enrollmentInfo":677,"targetDuration":4,"studyType":23,"phases":679,"briefSummary":680,"conditions":681,"keywords":683,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":690,"lastUpdatePostDateStruct":691,"startDateStruct":693,"completionDateStruct":695,"leadSponsor":697,"locationsCount":46},"100595445","metabotyping-of-broccoli-microgreen-in-obese-breast-cancer-survivors-100595445","NCT07032545","Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors","Metabotyping of a Functional Food, Broccoli Microgreen, in Obese Breast Cancer Survivors","Inclusion Criteria:\n\n* Female\n* Had a diagnosis of breast cancer (Stage I-III)\n* 2 to 60 months post-curative treatment (surgery, chemotherapy, and\u002For radiation)\n* BMI \\> 30 kg\u002Fm² (obese classification)\n* Willing to avoid cruciferous vegetables during the study\n* Able to sign an IRB-approved consent form\n\nExclusion Criteria:\n\n* Have any contraindications to the proposed nutrition intervention as identified by their medical provider, their designee, or the study team (e.g., GI conditions, medication requirements, pregnancy, breastfeeding, recent history of an eating disorder).\n* Allergy or intolerance to cruciferous vegetables\n* Currently taking broccoli extract supplements",{"count":678,"type":22},24,[25],"Obesity can pose significant challenges to maintaining long-term health in cancer survivors by increasing their risk of cancer coming back. Eating a healthy diet is an important way to help manage weight and improve overall health. Broccoli microgreens (BMG) are young broccoli plants packed with nutrients, and research suggests they may help prevent cancer.\n\nPrevious studies in mice showed that BMG can improve gut health and metabolism, leading to better health outcomes in obese animals. This study will test whether BMG can be a useful addition to the diet of obese breast cancer (BC) survivors who have a higher risk of their cancer returning.\n\n24 obese BC survivors will be invited to eat one serving (one cup, \\~57 gram) of fresh BMG every day for two weeks. This will help understand if people can stick to this diet, how their bodies respond, and whether it affects metabolism and inflammation-two key factors linked to cancer risk. Biological markers such as body fat, glucose and lipids as well as gut bacterial changes will be analyzed to see how BMG affects individual health.\n\nThis study may help create new diet strategies to improve health, reduce cancer risk, and support long-term recovery in cancer patients who are overweight or obese. In the future, this research could help doctors personalize nutrition plans to better support cancer survivors.",[30,682],"Breast Cancer Survivorship",[684,685,254,686,687,688,689],"breast cancer","broccoli microgreen","survivorship","gut microbiome","metabolomics","metabotyping","2025-12-16",{"date":692,"type":38},"2025-12-23",{"date":694,"type":38},"2025-12-03",{"date":696,"type":22},"2028-12-31",{"name":698,"class":45},"University of Maryland, Baltimore",{"id":700,"slug":701,"hasResults":12,"nctId":702,"briefTitle":703,"officialTitle":704,"acronym":4,"eligibilityCriteria":705,"healthyVolunteers":138,"sex":18,"minAge":706,"maxAge":707,"enrollmentInfo":708,"targetDuration":4,"studyType":23,"phases":710,"briefSummary":711,"conditions":712,"keywords":713,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":716,"lastUpdatePostDateStruct":717,"startDateStruct":719,"completionDateStruct":721,"leadSponsor":723,"locationsCount":46},"100480019","brainweighve-app-feasibility-study-100480019","NCT05530538","BrainWeighve App Feasibility Study","A Displacement Theory Mobile Health Weight Loss Intervention: A Pilot Clinical Trial","Inclusion Criteria:\n\n1. 14-21 years old\n2. Has an iPhone or are willing to use a study iPhone\n3. Ability to read and speak English\n4. Endorsement of one of the three items listed below on the five-item S-weight questionnaire indicating motivation for change During the last year I haven't done anything to lose weight but I'm planning to do something over the next 30 days.\n\nI've been making an effort to lose weight (by dieting1 and\u002For exercising2) for less than 6 months.\n\nI've been making an effort to maintain my weight (by dieting1 and\u002For exercising2) for more than 6 months.\n\n6\\. Body mass index \\[BMI\\] ≥85th percentile for age and gender\n\nExclusion Criteria:\n\n1. Any psychiatric condition and\u002For developmental delay which would require immediate or ongoing treatment that would make study participation difficult or harmful\n2. Parent\u002Fguardian-reported physical, mental of other inability to provide consent or refusal to provide consent for minor children\n3. Self-reported diagnosis of Prader-Willi Syndrome, brain tumor, hypothalamic obesity, or other diagnosis associated with obesity\n4. Concurrent participation in an alternative weight loss intervention\n5. Participation in the study team's previous app weight loss studies (exclusion for trial but not beta testing participants)","14 Years","21 Years",{"count":709,"type":22},38,[25],"Childhood obesity within the United States has been a growing concern over the past number of years, and if not addressed, leads to detrimental health outcomes for youth as they move into adulthood. The literature suggests that over-eating, especially when framed in terms of food addiction, plays a key role in this epidemic; however, treatment options are time intensive, posing a profound logistical barrier for both the child and parent and often limits or prevents engagement. As research within the field of mHealth has grown, technology-based interventions have gained traction, specifically interactive smartphone applications (apps). Displacement theory, although not new, has been understudied yet provides a strong explanation and treatment plan for addictive type behaviors. The core of this theory posits that problems which one feels they cannot face nor avoid leads to repetitive and irrepressible behaviors; however, if a healthy coping behavior can be learned and utilized, then the unhealthy behavior will cease. The theory lends itself well to being adapted into an mHealth format, making it more easily accessible and more widely used. Grounded in displacement theory, the proposed study aims to develop an app-based weight loss intervention for adolescents with obesity. Information gained regarding the feasibility and acceptability of such an intervention can potentially be replicated and applied to other populations with various addictive behaviors. Helping those with addictive behaviors in a format that has little to no logistical barriers can have a substantial impact on public health. A novel smartphone app will be designed by key stakeholders and refined through the course of the study. 38 total adolescents (14-21 years old) with %BMIp85 will be recruited via various sources (e.g., clinic referrals, flyers, social media advertising) to participate in one of two stages of the study: the beta testing stage or the trial stage. Beta testing will enroll one group of eight teens to test the app for three weeks; participants will be assessed in-person pre- and post-intervention. After each group, the app will be modified to incorporate their feedback in order to promote youth engagement. The trial stage will enroll 30 adolescents to participate in a four-month intervention; participants will complete three assessments, baseline, post-intervention (both in-person) and one-month post-intervention (either in-person or virtually). The study will examine engagement and satisfaction with the app, as well as the intervention's impact on clinical outcome measures (weight and BMI, diet and snacking, and addictive behaviors related to food and substance use) and potential mediators\u002Fmoderators (motivation for change, perceived stress, and distress tolerance).",[280,30],[280,714,715,64,400],"Adolescents","Smartphone App","2025-12-15",{"date":718,"type":38},"2025-12-22",{"date":720,"type":38},"2023-11-01",{"date":722,"type":22},"2027-07",{"name":724,"class":45},"University of California, Los Angeles"]